Halozyme Therapeutics | HALO - Operating Profit

Stock Price
80.82
Daily Change
2.40 3.06%
Monthly
7.60%
Yearly
41.54%
Q1 Forecast
69.50

Halozyme Therapeutics reported $217.92M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
Agios Pharmaceuticals USD -116.87M 10.19M Sep/2025
Alnylam Pharmaceuticals USD -29.96M 13.76M Sep/2025
Amarin USD -1.7M 8.47M Sep/2025
Amgen USD 3.96B 464M Dec/2025
Baxter International USD 201.2M 70.8M Sep/2025
Cytokinetics USD -166.76M 55.25M Sep/2025
DBV Technologies USD -34.28M 6.83M Sep/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Halozyme Therapeutics USD 217.92M 15.48M Sep/2025
Ionis Pharmaceuticals USD -160.18M 300.02M Sep/2025
MannKind USD -41.05M 2.36M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
United Therapeutics USD 389.3M 112.4M Sep/2025